IMMUTEP LIMITED (IMM)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IMM - IMMUTEP LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.03
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.31

06 Dec
2023

0.000

OPEN

$0.31

0.000

HIGH

$0.32

678,924

LOW

$0.30

TARGET
$0.55 77.4% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . ANP . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MXC . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PNV . PXS . PYC . RAC . RCE . RNO . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
IMM: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx - 4.5 - 3.9 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-4.5
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx-
Book Value Per Share xxxxxxxxxxxxxxx11.5
Net Operating Cash Flow xxxxxxxxxxxxxxx-35.4 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-34.61 %
Return on Invested Capital xxxxxxxxxxxxxxx-34.22 %
Return on Assets xxxxxxxxxxxxxxx-31.97 %
Return on Equity xxxxxxxxxxxxxxx-34.61 %
Return on Total Capital xxxxxxxxxxxxxxx-38.49 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-35.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx0 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx123 M
Price To Book Value xxxxxxxxxxxxxxx2.74

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx0.1 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx2 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx43 M
Research & Development xxxxxxxxxxxxxxx29 M
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

25/10/2023

1

Buy

$0.55

77.42%

Immutep has published data from two clinical trials in small cell lung cancer, and Bell Potter considers the results from the Phase 2 Efti plus pembrolizumab trials to be impressive.

The median overall survival rate of 35.5 months in the latter is double historical data for other treatments; and the three-year survival rate of 46% of patients is sharply higher than alternatives, observes the broker.

Bell Potter believes if the Phase 3 trials replicate these data, Efti would prove a considerable improvement on current treatments.

Buy rating and 55c target price retained.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -3.90 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.20 cents.
Access Stockbroker Research History >

IMM STOCK CHART

FNArena News on IMM

1
Australian Broker Call *Extra* Edition – Oct 27, 2023

Oct 27 2023 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Oct 24, 2023

Oct 24 2023 - Daily Market Reports
3
Rudi’s View: Yield Is Back

Oct 18 2023 - Rudi's View
4
FNArena Corporate Results Monitor – 04-09-2023

Sep 04 2023 - Australia
5
Rudi’s View: Low Expectations Not Low Enough?

Jul 19 2023 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: PYC Therapeutics

Nov 22 2023 - Small Caps
2
Dr Boreham’s Crucible: Paradigm Biopharmaceuticals

Nov 06 2023 - Small Caps
3
Dr Boreham’s Crucible: Argenica Therapeutics

Sep 28 2023 - Small Caps
4
Dr Boreham’s Crucible: Cleo Diagnostics

Aug 30 2023 - Small Caps
5
Breaking Boundaries: Medical Psychedelics

Aug 21 2023 - Small Caps
6
Momentum Keeps Building For Avita Medical

Aug 15 2023 - Small Caps
7
Dr Boreham’s Crucible: IDT Australia

Aug 14 2023 - Small Caps
8
Treasure Chest: Less Smooth Road Ahead For CSL

Aug 01 2023 - Treasure Chest
9
Dr Boreham’s Crucible: Telix Pharmaceuticals

Jul 31 2023 - Small Caps
10
Dr Boreham’s Crucible: Arovella Therapeutics

Jul 17 2023 - Small Caps